Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naderin for Prophylaxis of Hematologic Complications in Breast Cancer
NCT07671547Phase 3Completed
- Sponsor
- MIPO Clinic
- Start
- Jan 2014
- Primary completion
- Dec 2015
01
Overview
Phase 3, open-label trial in myelosuppression and leukopenia (2 arms), sponsored by MIPO Clinic. Primary endpoint: Incidence of leukopenia during chemotherapy at 4 months. Started Jan 2014; status: completed.
02
Conditions
myelosuppressionleukopenia
Beyond the preview
Go deeper on NCT07671547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07671547.